Loading stock data…
BridgeBio Oncology Therapeutics (BBOT)
N/A
Market Closed
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
Historical Price
No chart data available for BBOT
Whystock Brain
The Narrative
BridgeBio Oncology Therapeutics, Inc. in the Healthcare sector is trading at $7.66 with a market capitalization of $605M. Wall Street consensus targets $25.11 (9 analysts), implying a +227.8% move over the next 12 months. The stock is currently near its 52-week low of $7.00, remaining 26.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +227.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$46.18M↓ | -$43.41M↑ | -$49.18M↓ | -$30.09M↓ | -$23.14M |
| Net Income | -$42.11M↓ | -$38.80M↑ | -$44.76M↓ | -$28.43M↓ | -$22.05M |
Peer Comparison
JNJUNHPFE
Fundamentals
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. Th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$605.21M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-41.39%
Volume
Today's trading volume
-
Recent News
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.